Contact a Lawyer Now
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 18, 2021 to file lead plaintiff applications in a securities class action lawsuit against Emergent BioSolutions Inc. (NYSE: EBS) .
Emergent and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On March 31, 2021, post-market, news media outlets reported that the Company’s employees at its Bayview facility had conflated or “mixed up” ingredients for the Johnson & Johnson and AstraZeneca COVID-19 vaccines, ruining up to 15 million doses of the J&J vaccine, and that this occurrence was not an isolated event but was part of a history of manufacturing issues at the Company’s plant.
On this news, shares of Emergent plummeted over 15% over the next two trading days, from a closing price of $92.91 per share on March 31, 2021, to close at $78.62 on April 5, 2021.
If you purchased shares of Emergent and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (email@example.com), or fill out the form on this page.
The case is Palm Tran, Inc. – Amalgamated Transit Union Local 1577 Pension Plan v. Emergent Biosolutions Inc. et al, 8:21cv955.
Click here to read the case complaint.